TELA BIO INC (TELA) Stock Price, Quote, News and Overview
NASDAQ:TELA - Nasdaq - US8723811084 - Common Stock - Currency: USD
TELA Quote, Performance and Key Statistics
1.92
+0.06 (+3.23%)
The current stock price of TELA is 1.92 USD. In the past month the price increased by 90.1%. In the past year, price decreased by -64.18%.
TELA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ALC | ALCON INC | 29.65 | 44.45B | ||
| COO | COOPER COS INC/THE | 18.73 | 14.54B | ||
| ALGN | ALIGN TECHNOLOGY INC | 20.16 | 13.63B | ||
| SOLV | SOLVENTUM CORP | 12.7 | 13.07B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 26.66 | 5.62B | ||
| LNTH | LANTHEUS HOLDINGS INC | 12.15 | 5.56B | ||
| BLCO | BAUSCH + LOMB CORP | 26.21 | 4.45B | ||
| HAE | HAEMONETICS CORP/MASS | 15.79 | 3.47B | ||
| ICUI | ICU MEDICAL INC | 19.6 | 3.37B | ||
| XRAY | DENTSPLY SIRONA INC | 9.77 | 3.27B | ||
| UFPT | UFP TECHNOLOGIES INC | 29.21 | 1.84B | ||
| NEOG | NEOGEN CORP | 15.37 | 1.27B |
Related stock screener links
About TELA
Company Profile
TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company is headquartered in Malvern, Pennsylvania and currently employs 209 full-time employees. The company went IPO on 2019-11-08. The firm is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The firm's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
Company Info
TELA BIO INC
1 Great Valley Parkway, Suite 24
Malvern PENNSYLVANIA 19355 US
CEO: Antony Koblish
Employees: 209
Phone: 14843202930
TELA BIO INC / TELA FAQ
What is the stock price of TELA BIO INC today?
The current stock price of TELA is 1.92 USD. The price increased by 3.23% in the last trading session.
What is the ticker symbol for TELA BIO INC stock?
The exchange symbol of TELA BIO INC is TELA and it is listed on the Nasdaq exchange.
On which exchange is TELA stock listed?
TELA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TELA BIO INC stock?
11 analysts have analysed TELA and the average price target is 5.71 USD. This implies a price increase of 197.5% is expected in the next year compared to the current price of 1.92. Check the TELA BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TELA BIO INC worth?
TELA BIO INC (TELA) has a market capitalization of 75.94M USD. This makes TELA a Micro Cap stock.
How many employees does TELA BIO INC have?
TELA BIO INC (TELA) currently has 209 employees.
What are the support and resistance levels for TELA BIO INC (TELA) stock?
TELA BIO INC (TELA) has a support level at 1.91 and a resistance level at 1.93. Check the full technical report for a detailed analysis of TELA support and resistance levels.
Is TELA BIO INC (TELA) expected to grow?
The Revenue of TELA BIO INC (TELA) is expected to grow by 15.18% in the next year. Check the estimates tab for more information on the TELA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy TELA BIO INC (TELA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TELA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TELA, evaluating the profitability, health, valuation and growth aspects
- TELA BIO INC (TELA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TELA BIO INC (TELA) Sales and EPS estimates to see what analysts future expectations are.
- TELA BIO INC (TELA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TELA BIO INC (TELA) Insider and Institutional Ownership to learn about the owners and their transactions.
- TELA BIO INC (TELA) Stock Chart to make your own analysis
- TELA BIO INC (TELA) Latest news and press-releases to stay up to date.
Does TELA BIO INC (TELA) stock pay dividends?
TELA does not pay a dividend.
When does TELA BIO INC (TELA) report earnings?
TELA BIO INC (TELA) will report earnings on 2025-08-11, after the market close.
What is the Price/Earnings (PE) ratio of TELA BIO INC (TELA)?
TELA BIO INC (TELA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.41).
What is the Short Interest ratio of TELA BIO INC (TELA) stock?
The outstanding short interest for TELA BIO INC (TELA) is 1.64% of its float. Check the ownership tab for more information on the TELA short interest.
TELA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to TELA. When comparing the yearly performance of all stocks, TELA is a bad performer in the overall market: 94.75% of all stocks are doing better.
TELA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TELA. TELA may be in some trouble as it scores bad on both profitability and health.
TELA Financial Highlights
Over the last trailing twelve months TELA reported a non-GAAP Earnings per Share(EPS) of -1.41. The EPS increased by 15.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -56.24% | ||
| ROE | -239.72% | ||
| Debt/Equity | 2.28 |
TELA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to TELA. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 47.83% and a revenue growth 15.18% for TELA